Every action the European Heart Network (EHN) undertakes aims to achieve its mission: to prevent and reduce cardiovascular disease (CVD).

To establish its operational objectives and construct its work programme for 2018, EHN has scanned the EU policy horizon and consulted widely with its members.

EU policy areas upon which we will act include sustainable development, common agriculture policy and trade. We aim to inject consideration of CVD/chronic diseases into these areas to help achieve SDG goal 3.4 and the WHA 25x25 targets.

A major focus in 2018 is implementation of EHN’s policy recommendations contained in its paper “Transforming European food and drink policies for cardiovascular health”.

EHN is a closely-knit member organisation and has, consequently, planned a series of workshops and seminars to strengthen its members' capacities and provide knowledge-exchange opportunities for them. EHN will also strengthen its own operations and continue to ensure good governance.

EHN’s near-to-final 2019-2023 strategy encompasses three pillars (general objectives): I-prevent avoidable CVD; II-strengthen the support for people with CVD; III-reinforce CVD research. These pillars are supported by horizontal objectives and our 2018 work programme includes, notably, an operational objective to ensure a framework of strong cooperation with institutional as well as non-governmental, like-minded organisations working to promote health and reduce risk factors.

In conclusion, we believe that the 10 operational objectives and activities that we have selected for 2018 will contribute to achieve the general and specific objectives set out in our Framework Programme Application of June 2017. We believe that, collectively and albeit in the longer term, they will help address the large inequalities due to CVD in the EU and thus provide substantial EU added value.



The EURIPID Collaboration operating since 2010 is a voluntary collaboration of the European authorities in charge of pricing and reimbursement of pharmaceuticals for the mutual sharing of information related to the pricing of medicinal products via an online accessible up-to-date, and comprehensive database including the vast majority of EU Member States. The current proposal aims at supporting the voluntary cooperation between the national authorities by continuing the information provision on the existence of managed entry agreements, prices and sales volumes of reimbursable medicinal products, by enhancing the services to the users and also to general public and by strengthening the cooperation in the field of pricing of medicinal products between the national authorities and the stakeholders of the pharmaceutical sector, with a special focus on the European Medicines Agency (EMA), the European Medicines Verification Organisation and Eurostat.
The proposal foresees the creation of enhanced public interfaces of the EURIPID website and the establishment of regular newsletters so that the Collaboration will share more information about its activity with the general public; the spreading of the recommendations of the technical Guidance Document which are going to be prepared jointly by the national competent authorities and the stakeholders; the extension of the data content of the database to non-reimbursed but regulated priced products.
The terms of a formalised cooperation with the stakeholders will be defined so that the regular platform for information exchange will be established. The platform will discuss the options for the extension of the access to the EURIPID website, the options for sharing real price information between the Member States and the possibilities of cooperation between the EURIPID Collaboration and other ongoing projects like Article 57 database of EMA and the European Medicines Verification System.

